Pembrolizumab increases long-term survival in patients with advanced NSCLC

Share :
Published: 11 Jun 2019
Views: 1475
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Dr Jorge Nieva speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest results from the KEYNOTE-001 study, in which patients with advanced NSCLC were treated with pembrolizumab.

Dr Nieva notes the importance of this trial, which demonstrated that this immunotherapy aided the long-term survival of these patients and could possibly be a curative treatment in the future.


LBA9015 is a very important abstract because it moves us from an understanding of systemic therapies for cancer, from things that provided palliation, to things that provide cure. The surgeons have been talking about curing lung cancer for a very long time and as medical oncologists we haven’t really had a chance to do that because all of our therapies in the past prolonged life without completely eliminating the disease.

The very exciting thing about the five year follow-up of the KEYNOTE-001 study is that it demonstrated that many of our patients are long-term survivors with these therapies. Dare I say, we’re curing patients with immunotherapy for cancer. That’s probably the most exciting thing that has happened in cancer medicine in the last fifty years.